Tonix Pharmaceuticals (NASDAQ:TNXP) Stock: Insider Seth Lederman Buys 5,000 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman bought 5,000 shares of the business’s stock in a transaction on Wednesday, November 11th. The stock was acquired at an average cost of $4.05 per share, for a total transaction of $20,250.00. Following the completion of the transaction, the chief executive officer owned 16,005 shares in the company, valued at $64,820.25. This represents a 45.43% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Seth Lederman also recently made the following trade(s):

• On Thursday, August 27th, Seth Lederman bought 2,000 shares of Tonix Pharmaceuticals stock. The stock was bought at an average cost of $13.79 per share, with a total value of $27,580.00.

Tonix Pharmaceuticals Trading Down 7.1%

NASDAQ TNXP traded down $0.23 on Friday, hitting $3.01. 1,924,597 shares of the stock traded hands, compared to its average volume of 1,025,831. The stock has a 50-day moving average of $7.72 and a 200 day moving average of $11.85. Tonix Pharmaceuticals Holding Corp. has a twelve month low of $2.90 and a twelve month high of $20.56. The company has a market capitalization of $58.48 million, a P/E ratio of -0.25 and a beta of 1.90.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Monday, November 9th. The company reported ($2.89) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.50). Tonix Pharmaceuticals had a negative net margin of 420.45% and a negative return on equity of 80.97%. The business had revenue of $17.23 million during the quarter, compared to analyst estimates of $16.32 million. As a group, equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -10.42 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on TNXP. Canaccord Genuity Group began coverage on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. They issued a “buy” rating and a $18.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. Raymond James Financial reissued a “strong-buy” rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, October 20th. Finally, Wall Street Zen cut Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $22.33.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of institutional investors have recently bought and sold shares of TNXP. Empowered Funds LLC purchased a new position in Tonix Pharmaceuticals during the third quarter valued at approximately $192,000. Steward Partners Investment Advisory LLC purchased a new stake in Tonix Pharmaceuticals in the 3rd quarter worth approximately $39,000. Global Retirement Partners LLC purchased a new stake in Tonix Pharmaceuticals in the 3rd quarter worth approximately $28,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter valued at $92,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter valued at $533,000. 82.26% of the stock is currently owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.